作者: Mark Slack , Donald Ostergard , Mauro Cervigni , Jan Deprest
DOI: 10.1007/S00192-012-1678-2
关键词:
摘要: Over the past decade, a huge number of new implants and ancillary devices have been introduced to market. Most these become clinically available with little or no clinical data research. This is less-than-ideal situation, this subgroup ad hoc IUGA roundtable conference wants open discussion change this, by proposing pragmatic minimum clearance track for products being It consists an accurate more standardized product description, on biological properties gathered in animal experiments, anatomical cadaveric studies, upfront studies followed compulsory registry first 1,000 patients implanted. Ideally, manufacturers should support well-designed prospective (randomized) trials that can claimed benefits product.